Bevacizumab specifically decreases elevated levels of circulating KIT(+)CD11b(+) cells and IL-10 in metastatic breast cancer patients

BACKGROUND: Whether bevacizumab exerts its anti-tumor properties through systemic effects beyond local inhibition of angiogenesis and how these effects can be monitored in patients, remain largely elusive. To address these questions, we investigated bone marrow-derived cells and cytokines in the per...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattin, Sarah, Fellay, Benoît, Pradervand, Sylvain, Trojan, Andreas, Ruhstaller, Thomas, Rüegg, Curzio, Fürstenberger, Gregor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905463/
https://www.ncbi.nlm.nih.gov/pubmed/26840567
http://dx.doi.org/10.18632/oncotarget.7097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905463/
https://www.ncbi.nlm.nih.gov/pubmed/26840567
http://dx.doi.org/10.18632/oncotarget.7097

Ejemplares similares